Affimed NV (AFMDQ)

Currency in USD
0.020
-0.010(-33.33%)
Closed·
AFMDQ Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 8 days
Fair Value
Day's Range
0.0200.020
52 wk Range
0.0105.480
Key Statistics
Prev. Close
0.03
Open
0.02
Day's Range
0.02-0.02
52 wk Range
0.01-5.48
Volume
1.55K
Average Volume (3m)
16.14M
1-Year Change
-99.42%
Book Value / Share
1.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AFMDQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Affimed NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Affimed NV Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Compare AFMDQ to Peers and Sector

Metrics to compare
AFMDQ
Peers
Sector
Relationship
P/E Ratio
0.0x−2.5x−0.5x
PEG Ratio
0.000.030.00
Price/Book
0.0x1.3x2.6x
Price / LTM Sales
0.1x8.7x3.2x
Upside (Analyst Target)
-71.8%42.0%
Fair Value Upside
Unlock7.6%6.6%Unlock

Earnings

Latest Release
May 21, 2025
EPS / Forecast
-0.35 / -0.5655
Revenue / Forecast
-- / 1.27M
EPS Revisions
Last 90 days

AFMDQ Income Statement

People Also Watch

0.99
KLTO
+3.24%
7.880
HYPD
-10.05%
16.5400
INKT
-0.96%
0.047
NCNA
-7.16%
3.470
ATAI
+4.83%

FAQ

What Stock Exchange Does Affimed NV Trade On?

Affimed NV is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Affimed NV?

The stock symbol for Affimed NV is "AFMDQ."

What Is the Affimed NV Market Cap?

As of today, Affimed NV market cap is 327.85K.

What Is Affimed NV's Earnings Per Share (TTM)?

The Affimed NV EPS (TTM) is -4.54.

When Is the Next Affimed NV Earnings Date?

Affimed NV will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is AFMDQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Affimed NV Stock Split?

Affimed NV has split 1 times.

How Many Employees Does Affimed NV Have?

Affimed NV has 76 employees.

What is the current trading status of Affimed NV (AFMDQ)?

As of 30 Jul 2025, Affimed NV (AFMDQ) is trading at a price of 0.02, with a previous close of 0.03. The stock has fluctuated within a day range of 0.02 to 0.02, while its 52-week range spans from 0.01 to 5.48.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.